The study found that patients with high levels of pDC, NSCLC in stages I to III, and without metastatic disease, had better OS than patients with low pDC levels, with a mean OS of 30.4 versus 20.7 months (P = 0.013). This evidence concerns the gene PDC and non-small cell lung carcinoma.